[1]刘 鹏,陈青山,杨建波.柴胡疏肝散加减联合射频消融治疗肝癌疗效研究[J].陕西中医,2023,(7):892-896.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
　LIU Peng,CHEN Qingshan,YANG Jianbo.Curative effect study on Chaihu Shugan powder combined with radiofrequency ablation for liver cancer[J].,2023,(7):892-896.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.015]
点击复制

柴胡疏肝散加减联合射频消融治疗肝癌疗效研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年7期
页码:
892-896
栏目:
临床研究
出版日期:
2023-07-05

文章信息/Info

Title:
Curative effect study on Chaihu Shugan powder combined with radiofrequency ablation for liver cancer
作者:
刘 鹏; 陈青山; 杨建波
(湖南中医药大学第一附属医院肝胆外科,湖南 长沙 410021)
Author(s):
LIU Peng; CHEN Qingshan; YANG Jianbo
(Department of Hepatobiliary,the First Affiliated Hospital of Hunan University of Chinese Medicine,Changsha 410021,China)
关键词:
肝癌;  柴胡疏肝散;  射频消融;  存活率;  复发
Keywords:
Liver cancer;  Chaihu Shugan powder;  Radiofrequency ablation;  Survival rate;  Recrudescence
分类号:
R 273
DOI:
DOI:10.3969/j.issn.1000-7369.2023.07.015
文献标志码:
A
摘要:
目的:探讨柴胡疏肝散加减对射频消融(RFA)治疗后不可切除肝癌患者预后的影响。方法:选择RFA治疗的85例不可切除的肝癌患者为研究对象,采用随机数字表法分为对照组(n=42)、观察组(n=43)。对照组采用RFA治疗,观察组采用RFA联合柴胡疏肝散加减治疗,两组均治疗2个月。出院后随访,比较两组患者并发症、总生存率、肝内无复发生存率等指标。结果:观察组中40例患者治疗成功,其中16例完成1个RFA疗程,20例完成2个疗程,4例完成3个疗程。对照组22例完成1个疗程的RFA,8例完成2个疗程,4例完成3个疗程。64例患者在RFA治疗后的3年内死亡,其中对照组40例、观察组24例,观察组3年总生存率高于对照组(P<0.05)。在RFA开始后3年内对照组肝内复发19例、观察组8例,观察组肝内无复发生存率高于对照组(P<0.05)。肿瘤直径>5 cm、肿瘤低分化是影响总生存率、复发的独立危险因素,柴胡疏肝散加减是独立保护因素; 肝硬化是肝癌复发的独立危险因素,但对总生存率无明显影响。结论:柴胡疏肝散加减可增加RFA治疗成功率,提高不可切除肝癌患者总存活率。
Abstract:
Objective:To explore effect of Chaihu Shugan powder on prognosis of patients with unresectable hepatocellular carcinoma after radiofrequency ablation(RFA).Methods:85 patients with unresectable hepatocellular carcinoma were selected as study subjects,using random number table method divided into control group(n=42)and observation group(n=43).The control group were treated with RFA,and the observation group treated with RFA combined with Chaihu Shugan powder.Both groups were treated for 2 months.After discharge,patients were closely followed up.Compare complications,overall survival rate,and intrahepatic recurrence free survival rate between the two groups.Results:In the observation group,40 patients were successfully treated,which 16 completed 1 RFA course,20 completed 2 courses,and 4 completed 3 courses.In the control group,22 patients completed 1 RFA,8 patients completed 2 RFA,and 4 patients completed 3 RFA.64 patients died within 3 years after RFA treatment,including 40 in the control group and 24 in the observation group.3-year overall survival rate in the observation group were significantly higher than that in the control group(P<0.05).Within 3 years after the start of RFA,19 patients in the control group and 8 patients in the observation group had intrahepatic recurrence,and the survival rate of intrahepatic recurrence in the observation group was higher than that in the control group(P<0.05).Tumor diameter greter 5 cm and low tumor differentiation were independent risk factors affecting overall survival and recurrence.Chaihu Shugan powder was an independent protective factor.Cirrhosis was an independent risk factor for hepatocellular carcinoma recurrence,but has no significant effect on overall survival.Conclusion:Chaihu Shugan powder can increase the success rate of RFA treatment and improve overall survival rate of patients with unresectable liver cancer.

参考文献/References:

[1] 中华人民共和国国家卫生健康委员会.原发性肝癌诊疗指南[J].传染病信息,2022,35(1):1-26.
[2] 明志强,曹金明,陈天武,等.肝细胞癌射频消融术后疗效的MRI评价[J].磁共振成像,2022,13(5):115-119.
[3] 赫 嵘,贾 哲,蒋 力,等.三维可视化消融辅助系统在肝细胞癌射频消融术中的应用价值[J].临床肝胆病杂志,2022,38(9):2046-2052.
[4] 何 坤,何泳铸,胡泽民,等.肝癌射频消融术后复发危险因素分析及术前预测评分[J].中华肝胆外科杂志,2021,27(3):169-174.
[5] 张 翔,白人驹.肝癌射频消融治疗后并发症的影像学表现及治疗[J].医学影像学杂志,2022,20(2):284-286.
[6] 张金付.柴胡疏肝散联合富马酸替诺福韦二吡呋酯治疗肝郁气滞型慢性乙型肝炎临床观察[J].中国中医药现代远程教育,2022,24(19):121-123.
[7] 刘红枝,刘景丰.人工智能在原发性肝癌外科治疗中的应用现状与展望[J].临床肝胆病杂志,2022,38(1):10-14.
[8] 赵培西,许建秦,袁 彬,等.扶正抗癌方治疗肝癌肝郁脾虚瘀毒证临床研究[J].陕西中医,2022,43(12):1746-1748.
[9] 李 丹,赵 飞,王树庚.疏肝健脾散结汤联合肝动脉插管化疗栓塞术治疗原发性肝癌疗效研究[J].陕西中医,2021,42(6):728-731.
[10] 吕 妍.柴胡疏肝散治疗杂病验案4则[J].天津中医药,2020,37(9):1053-1056.
[11] 刘文雯,木本荣,馨 钟,等.基于网络药理学和生物信息学探索逍遥散和柴胡疏肝散“同病异治”抑郁症的作用机制[J].中医学,2021,10(2):200-215.
[12] 张兆鹏,闫 俏,马欣宇,等.加味柴胡疏肝散通过调控Akt/GSK-3β/Nrf2信号通路抑制小鼠酒精性肝损伤[J].中国老年学杂志,2023,12(5):1163-1166.
[13] 程瑞文,李 平,邓梨平.TACE序贯柴胡疏肝散治疗肝郁脾虚型肝癌的临床研究[J].中医药导报,2016,22(20):20-23.
[14] 贾 哲,赫 嵘,黄容海,等.同期肝癌射频消融联合Hassab手术对肝细胞癌合并门静脉高压患者细胞免疫功能的影响[J].中国肝脏病杂志:电子版,2022,14(3):61-67.
[15] 许 斌,俞 渊.射频消融治疗原发性肝癌的研究进展[J].医药前沿,2020,29(10):9-11.
[16] 尹常健.中医药治疗肝癌的几个理论与实践问题[J].中西医结合肝病杂志,2019,29(2):112-113.
[17] 李紫瑞,王 坚,王瑞平.中医疏肝健脾法治疗肝癌的研究进展[J].现代中西医结合杂志,2021,30(21):2383-2388.
[18] 孔令玉,孙江勇,刘 靖,等.肝癌微创介入治疗中医药应用进展及探索[J].医学理论与实践,2021,34(23):4073-4075,4078.
[19] 王亚琪,曾普华,郜文辉.益气化瘀解毒方联合索拉非尼对人肝癌索拉非尼耐药细胞移植瘤及缺氧诱导因子1α与血管拟态表达的影响[J].陕西中医,2020,41(2):143-146.
[20] 曹如柔,周 坚,王其美,等.莪术二酮通过VEGF/VEGFR2信号通路对肝癌HepG2细胞微环境下HHSEC增殖的影响[J].湖南中医药大学学报,2021,41(12):1835-1839.
[21] 吴 铭,高英恺,刘存军,等.自拟通窍方联合低温等离子射频消融治疗气滞血瘀型鼻窒临床研究[J].广州中医药大学学报,2022,39(2):317-323.
[22] 周 用,左 盼,吴哲骁,等.扶正消瘤方治疗肝动脉化疗栓塞术加经皮肝肿瘤射频消融术后肝癌临床研究[J].陕西中医,2020,41(11):1534-1538.
[23] 冀卓然,王 曼,郝明霞,等.化肝汤对原发性肝癌患者经TACE和RFA治疗预后的影响[J].湖南中医药大学学报,2022,42(12):2077-2082.
[24] 姜 飞,王东玉.依达拉奉右莰醇联合尿激酶静脉溶栓治疗急性脑梗死合并糖尿病对患者血清氧化应激水平、颈总动脉内-中膜厚度、血清基质金属蛋白酶-12水平的影响[J].陕西医学杂志,2022,51(1):88-91.
[25] 尹秀凤,华美娟,朱红娣.孕晚期妊娠期糖尿病患者糖化血红蛋白水平与胎儿体质量、新生儿Apgar评分及母婴不良结局的相关性[J].中国医师进修杂志,2021,44(8):691-695.
[26] 肖 婷.人软骨糖蛋白-40、热休克蛋白-70及儿茶酚胺对急性冠脉综合征患者病情严重程度的预警作用研究[J].陕西医学杂志,2023,52(4):445-447,451.
[27] 王 玲,申 鸿. 癌胚抗原、糖类抗原、CA125、血管生成素、细胞角蛋白19片段及甲胎蛋白检测在肺癌诊断中的临床研究[J].陕西医学杂志,2019,48(8):1080-1084.
[28] 罗 铎,欧志涛,黄 韫,等.原发性肝癌患者血清AFP、AFP-L3、PIVKA-Ⅱ水平及与病理特征和预后的关系分析[J].现代消化及介入诊疗,2022,12(2):140-143.
[29] 王玲玲,赵含信,周 艳,等.miR-155、TSGF、AFP在肝细胞肝癌预后中的评估价值[J].齐齐哈尔医学院学报,2022,23(7):614-617.

相似文献/References:

[1]李 恒,穆 恒△.柴胡疏肝散联合西药治疗肝胃不和型功能性消化不良疗效及对患者血清胃肠激素水平的影响[J].陕西中医,2020,(7):904.[doi:DOI:10.3969/j.issn.10007369.2020.07.019]
[2]曹伊媛,陈 颖,周 薏,等.基于网络药理学研究柴胡疏肝散治疗急性胰腺炎的作用机制*[J].陕西中医,2020,(7):994.[doi:DOI:10.3969/j.issn.10007369.2020.07.047]
　CAO Yiyuan,CHEN Ying,ZHOU Yi,et al.Study on the mechanism of Chaihu Shugan san in treating acute pancreatitis based on network pharmacology[J].,2020,(7):994.[doi:DOI:10.3969/j.issn.10007369.2020.07.047]
[3]肖 岚,朱 宏,张 婷,等.董克礼教授治疗原发性肝癌临床经验*[J].陕西中医,2020,(11):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
　XIAO Lan,ZHU Hong,ZHANG Ting,et al.Experience of professor DONG Keli for treating primary liver cancer[J].,2020,(7):1639.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.032]
[4]王 军,徐建良,杜燕红.扶正祛邪汤对肝癌模型大鼠肠道菌群微生态环境的作用研究[J].陕西中医,2021,(2):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
　WANG Jun,XU Jianliang,DU Yanhong.Effect of Fuzheng Quxie decoction on intestinal microflora microecological environment of liver cancer model rats[J].,2021,(7):143.[doi:DOI:10.3969/j.issn.1000-7369.2020.02.002]
[5]朱玉辉,柴 劲.黄芪补气汤联合还原型谷胱甘肽对肝癌介入治疗后患者肝功能、氧化应激及炎症的影响[J].陕西中医,2021,(5):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
　ZHU Yuhui,CHAI Jin.Effect of Huangqi Buqi decoction combined with reduced glutathione on liver function,oxidative stress and inflammation after interventional therapy for hepatocellular carcinoma[J].,2021,(7):570.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.006]
[6]王 峰,王宝凯,曲更宝,等.柴胡疏肝散加减对乳腺增生患者局部症状及血清性激素水平的影响[J].陕西中医,2021,(7):853.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.009]
　WANG Feng,WANG Baokai,QU Gengbao,et al.Effect of modified Chaihu Shugan powder on local symptoms and serum sex hormone levels in patients with hyperplasia of mammary glands[J].,2021,(7):853.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.009]
[7]刘振方,孙巧玉,孟祥彩,等.黄芩素下调微小RNA-130a抑制肝癌细胞侵袭机制研究[J].陕西中医,2021,(12):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
　LIU Zhenfang,SUN Qiaoyu,MENG Xiangcai,et al.Study on mechanism of baicalein down-regulating miR-130a to inhibit hepatocellular carcinoma invasion[J].,2021,(7):1667.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.003]
[8]李武浩,许尤琪.中医药防治肝动脉灌注化疗相关不良反应研究进展[J].陕西中医,2022,(5):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
　LI Wuhao,XU Youqi.Clinical research progress of traditional Chinese medicine on the prevention and treatment of related adverse reaction of hepatic artery infusion chemotherapy[J].,2022,(7):673.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.031]
[9]郑俊佳,黄 彬,郭绍举,等.疏肝和胃法治疗胆汁反流性胃炎临床疗效和安全性Meta分析[J].陕西中医,2022,(11):1638.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.035]
　ZHENG Junjia,HUANG Bin,GUO Shaoju,et al.Meta-analysis of clinical efficacy and safety of Shugan Hewei therapy for bile reflux gastritis[J].,2022,(7):1638.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.035]
[10]梁瀞云,唐 燕,司马玲,等.柴胡疏肝散在肝脏疾病中的应用研究进展[J].陕西中医,2022,(11):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]
　LIANG Jingyun,TANG Yan,SIMA ling,et al.Application of Chihu Shugan powder in liver diseases[J].,2022,(7):1651.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.038]

备注/Memo

备注/Memo:
基金项目:湖南省自然科学基金资助项目(2022JJ40330); 湖南省卫生健康委员会科研计划项目(202304019027)
更新日期/Last Update: 2023-07-10